Severe aplastic anemia
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Must be able to understand the trial protocol, follow the doctor's instructions and sign the informed consent; 2. Aged = 3 months; 6. No serious comorbidities, AST, ALT, bilirubin within 2 weeks before enrollment is less than 2.5 times the upper limit of normal, serum creatinine is less than 2 times the upper limit of normal, myocardial enzyme is less than 2 times the upper limit of normal; 7. The viral hepatitis virus DNA copy number does not exceed 5x10^2 copy number; 8. Haplotype donors with HLA high-resolution matching (A, B, C, DR, DQ) haploidentical (>=5/10), the donor age is 8-65 years old, and there is no contraindication for donating stem cells (Excluding hematological diseases, malignant tumors, infectious diseases, severe organ insufficiency, mental diseases, etc.); 9. No active infection; 10. Females of reproductive age must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year.
Exclusion criteria
Exclusion criteria: 1. Diagnose paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, congenital genetic diseases and other diseases; 2. Specific allergic constitution, allergic to ruxolitinib; 3. HBV active viral hepatitis, HCV antibody positive, HIV positive; 4. Serious disease that may limit patient participation in this trial (eg, advanced infection: deep fungal infection and/or active infection, drug-resistant bacterial infection, sepsis, uncontrolled diabetes, severe cardiac insufficiency or angina pectoris, liver and kidney insufficiency, severe respiratory disease); 5. Those who are participating in other clinical trials or have participated in other drug clinical trials within 3 months; 6. Breastfeeding patients; 7. Mental state is unstable; 8. Patients who are deemed unsuitable for treatment by this regimen according to the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of acute graft-versus-host disease; | — |
Countries
China
Contacts
Public ContactYan Jinsong
The Second Affiliated Hospital of Dalian Medical University
Outcome results
None listed